Immediate Impact
1 by Nobel laureates 1 from Science/Nature 53 standout
Citing Papers
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
Lightweight and drift-free magnetically actuated millirobots via asymmetric laser-induced graphene
2024 Standout
Works of Paul Monk being referenced
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
2021
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Paul Monk | 222 | 162 | 82 | 99 | 50 | 376 | |
| Guangyu Bai | 160 | 124 | 58 | 105 | 32 | 359 | |
| Jindřich Kopecký | 216 | 161 | 82 | 102 | 49 | 450 | |
| Ayako Hirai | 205 | 211 | 84 | 81 | 51 | 455 | |
| T. Macarulla Mercadé | 283 | 120 | 139 | 147 | 56 | 442 | |
| Yasuyoshi Sato | 181 | 102 | 58 | 73 | 45 | 368 | |
| Marco Iafolla | 209 | 172 | 60 | 137 | 37 | 428 | |
| Fabiana Napolitano | 210 | 164 | 93 | 136 | 31 | 418 | |
| Till Plönes | 172 | 218 | 38 | 85 | 51 | 391 | |
| Prakash Neupane | 317 | 153 | 91 | 98 | 36 | 448 | |
| Mitsuro Fukuhara | 236 | 191 | 65 | 109 | 35 | 440 |
All Works
Login with ORCID to disown or claim papers
Loading papers...